{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:13:36Z","timestamp":1792512816720,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88881.200581\/201801"],"award-info":[{"award-number":["88881.200581\/201801"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["008\/2021"],"award-info":[{"award-number":["008\/2021"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["01.02.016301.03422\/2021-03"],"award-info":[{"award-number":["01.02.016301.03422\/2021-03"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["005\/2022"],"award-info":[{"award-number":["005\/2022"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114701","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:33:19Z","timestamp":1681450399000},"page":"114701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cytotoxic and immunomodulatory potential of a novel [2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)\u22121H-pyrazol-3-yl)pyridine] in myeloid leukemia"],"prefix":"10.1016","volume":"162","author":[{"given":"Carlos Eduardo","family":"de Castro Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-9541","authenticated-orcid":false,"given":"Georgyi","family":"Koidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia N.","family":"Hurieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"de Freitas Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regiane","family":"Costa de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Guimar\u00e3es Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Luiz","family":"Ribeiro Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Correa de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-2438","authenticated-orcid":false,"given":"Serhii","family":"Zahorulko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-4968","authenticated-orcid":false,"given":"Aleksandr","family":"Kostyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemilson","family":"Soares Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114701_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114701_bib2","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2023.114701_bib3","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.114701_bib4","unstructured":"WHO, WHO Global report on traditional and complementary medicine 2019, 2019. \u3008https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/312342\/9789241515436-eng.pdf?ua=1\u3009."},{"key":"10.1016\/j.biopha.2023.114701_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114701_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2023.114701_bib7","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","article-title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations","volume":"28","author":"Green","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114701_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic myeloid leukemia: beyond BCR-ABL1","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.biopha.2023.114701_bib9","first-page":"1","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114701_bib10","first-page":"115","article-title":"Ayurveda for chemo-radiotherapy induced side effects in cancer patients","volume":"8","author":"Metri","year":"2013","journal-title":"J. Stem Cells"},{"key":"10.1016\/j.biopha.2023.114701_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.biopha.2023.114701_bib12","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","article-title":"Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.114701_bib13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00120-017-0338-z","article-title":"Side effects of chemotherapy","volume":"56","author":"Hauner","year":"2017","journal-title":"Urol. A"},{"key":"10.1016\/j.biopha.2023.114701_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biopha.2023.114701_bib15","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","article-title":"Mechanisms of drug resistance in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2023.114701_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.biopha.2023.114701_bib17","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1002\/chem.201204199","article-title":"Structure\u2013Reactivity relationships in the hydrogenation of carbon dioxide with ruthenium complexes bearing pyridinylazolato ligands","volume":"19","author":"Muller","year":"2013","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.biopha.2023.114701_bib18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/molecules18010832","article-title":"Synthesis and antibacterial evaluation of novel heterocyclic compounds containing a sulfonamido moiety","volume":"18","author":"Azab","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.114701_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.arabjc.2012.04.003","article-title":"Synthesis, antimicrobial and anticancer activities of some new N-methylsulphonyl and N-benzenesulphonyl-3-indolyl heterocycles: 1st Cancer Update","volume":"6","author":"El-Sawy","year":"2013","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.biopha.2023.114701_bib20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ardp.201300183","article-title":"Synthesis, antibacterial, and antiviral evaluation of new heterocycles containing the pyridine moiety","volume":"346","author":"Salem","year":"2013","journal-title":"Arch. Pharm. (Weinh. )"},{"key":"10.1016\/j.biopha.2023.114701_bib21","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.114701_bib22","unstructured":"V. Berdini, M.A. O\u2019brien, M.G. Carr, N.G.M. Davies, A.L. Gill, E.F. Navarro, S. Howard, G. Trewartha, A.J. Woodhead, A.J.-A. Woolford, P.G. Wyatt, 2006. Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases, WO2006\/70198,2006,A1, 2006."},{"key":"10.1016\/j.biopha.2023.114701_bib23","first-page":"1","article-title":"Anticancer and immunomodulatory activities of a novel water-soluble derivative of ellipticine","volume":"25","author":"de Oliveira","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2023.114701_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-018-0507-1","article-title":"Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells","volume":"18","author":"Men","year":"2018","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.biopha.2023.114701_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0960327118756719","article-title":"Cytotoxicity, oxidative stress, and apoptosis in K562 leukemia cells induced by an active compound from pyrano-pyridine derivatives","volume":"37","author":"Mahdavi","year":"2018","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.biopha.2023.114701_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23010081","article-title":"Design, synthesis and biological evaluation of new substituted diquinolinyl-pyridine ligands as anticancer agents by targeting G-Quadruplex","volume":"23","author":"Das","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.114701_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/path.3022","article-title":"The cell cycle and cancer","volume":"226","author":"Williams","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2023.114701_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.114701_bib29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrm1493","article-title":"Checking on DNA damage in S phase","volume":"5","author":"Bartek","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114701_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127710","article-title":"Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors","volume":"31","author":"Xiang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2023.114701_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.36660\/abc.20210720","article-title":"Anti-Inflammatory effects of atorvastatin therapy in metabolic syndrome","volume":"117","author":"Oliveira-Junior","year":"2021","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.biopha.2023.114701_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/14756366.2018.1550085","article-title":"Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2-b]pyridazine and pyrrolo[2,1-a]phthalazine derivatives","volume":"34","author":"Popovici","year":"2019","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"10.1016\/j.biopha.2023.114701_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112783","article-title":"Bioactive pyrrole-based compounds with target selectivity","volume":"208","author":"Li Petri","year":"2020","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2023.114701_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.18433\/jpps32417","article-title":"Pyrrole as an important scaffold of anticancer drugs: recent advances","volume":"25","author":"Mateev","year":"2022","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.114701_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10534-011-9496-4","article-title":"Perspective: the potential of pyrazole-based compounds in medicine","volume":"25","author":"Keter","year":"2012","journal-title":"Biometals"},{"key":"10.1016\/j.biopha.2023.114701_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jinorgbio.2006.05.001","article-title":"Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands","volume":"100","author":"Ciesielska","year":"2006","journal-title":"J. Inorg. Biochem"},{"key":"10.1016\/j.biopha.2023.114701_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-008-0721-y","article-title":"In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents","volume":"63","author":"Keter","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2023.114701_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejmech.2018.05.036","article-title":"Pyridinium and indole orientation determines the mitochondrial uncoupling and anti-cancer efficiency of F16","volume":"154","author":"Xu","year":"2018","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2023.114701_bib39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/jpet.112.199216","article-title":"LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria","volume":"344","author":"Beckham","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114701_bib40","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.biopha.2023.114701_bib41","first-page":"721","article-title":"Biological Evaluation and Molecular Docking Study of 3-(4-Sulfamoylphenyl)-4-phenyl-1H-pyrrole-2,5-dione as COX-2 Inhibitor","volume":"33","author":"Chung","year":"2011","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/j.biopha.2023.114701_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1381612043453144","article-title":"Cyclooxygenase enzymes: regulation and function","volume":"10","author":"Fitzpatrick","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2023.114701_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772408","article-title":"Inflammatory cytokines shape an altered immune response during myeloid malignancies","volume":"12","author":"Camacho","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.114701_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1684\/ecn.2012.0322","article-title":"The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation","volume":"23","author":"Reikvam","year":"2012","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.biopha.2023.114701_bib45","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3324\/haematol.2020.270421","article-title":"Interleukin 4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation","volume":"107","author":"Pe\u00f1a-Mart\u00ednez","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2023.114701_bib46","first-page":"214","article-title":"Suppression of chronic myelogenous leukemia colony growth by interleukin-4","volume":"7","author":"Estrov","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.114701_bib47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20121229","article-title":"Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-\u03b3","volume":"210","author":"Sch\u00fcrch","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2023.114701_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.114701_bib49","first-page":"37","article-title":"Cytokine profiling as a prognostic markers in chronic myeloid leukemia patients","volume":"18","author":"Singer","year":"2011","journal-title":"Egypt J. Immunol."},{"key":"10.1016\/j.biopha.2023.114701_bib50","first-page":"1565","article-title":"Assessment of the Serum Level of Interleukin-6 and Interleukin-10 in Newly Diagnosed Acute Myeloid Leukemia Patients and the Response to Induction Chemotherapy","volume":"86","author":"Abd EL-Hafez","year":"2018","journal-title":"Med J. Cairo Univ."},{"key":"10.1016\/j.biopha.2023.114701_bib51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/02656736.2013.807440","article-title":"Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity","volume":"29","author":"Mikucki","year":"2013","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.biopha.2023.114701_bib52","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI44952","article-title":"IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells","volume":"121","author":"Fisher","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.114701_bib53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.13433","article-title":"Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity","volume":"109","author":"Tsukamoto","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2023.114701_bib54","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/1568009617666170427102729","article-title":"Impact of IL-12 in cancer","volume":"17","author":"Lu","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.biopha.2023.114701_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:38:20Z","timestamp":1778693900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223004894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":55,"alternative-id":["S0753332223004894"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114701","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytotoxic and immunomodulatory potential of a novel [2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)\u22121H-pyrazol-3-yl)pyridine] in myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114701"}}